CONCORDBIOConcord Biotech Limited
Convert to ideaPharmaceuticals & Biotechnology · Biotechnology
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹309 Cr | ₹70 Cr | 27.83% | 22.51% | ₹3.33 | Negligible |
| Q1 FY2027 | ₹257 Cr | ₹58 Cr | 24.96% | 22.41% | ₹2.76 | Negligible |
| Q4 FY2026 | ₹326 Cr | ₹88 Cr | 30.36% | 27.13% | ₹4.23 | Negligible |
| Q3 FY2026 | ₹278 Cr | ₹64 Cr | 28.88% | 22.91% | ₹3.04 | Negligible |
| Q2 FY2026 | ₹247 Cr | ₹63 Cr | 28.37% | 25.53% | ₹3.02 | Negligible |
| Q1 FY2026 | ₹204 Cr | ₹44 Cr | 21.38% | 21.60% | ₹2.10 | Negligible |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Biotechnology
Compare with peers →Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.